Three Visuals to Explain the Impact of Pharmacogenomic and Epigenetic Biomarkers in Oncology

This post was authored by Mike Madarasz of the Institute for International Research.  You can follow him on Twitter at @MikeMadarasz

In an effort to increase efficiency and streamline development of effective cancer therapies as well hold down costs associated with conducting clinical trials, drug developers have increased their investment in clinical biomarker research.  Specifically, there has been an increase in the use of pharmagenomic (PGX) biomarkers to either select or stratify patients.  Citeline recently published a white paper outlining some of the major impacts in oncology—some of which are explained in the charts below.

The increase in oncology trials selecting or stratifying by PGBX Biomarkers

The percentage of trials in this category has more than doubled since 2002

Breakdown of countries in PGX trials

The U.S. accounts for nearly 30% of these trials with Japan being the next closest at almost 15%.

Top sponsors using PGX biomarkers to select/stratify patients

The National Cancer Institute comes out as the top sponsor both in the relative     sense and in number of PGX trials.

To check out more from Citeline, download the white paper here.

You can hear more from top industry thought leaders. Check out the Biorepositories and Sample Management Conference. 

September 8-10, 2015 | Boston, MA

Register here. Discount code: XP1998BLOG

Free Webinar-Breadth and Depth: Oh, What a Data-Rich Biorepository Can Do for Your Research!
DATE: April 30, 2014, 2:00 PM - 3:00PM EST 
Register here

Discount Code: XP1998BLOG

Share this article with your social network, just click below to share now!

Share |